July 26, 2017
Written by Jennifer Garam
This article originally appeared on Johnson & Johnson’s website.
As the International AIDS Society Conference on HIV Science kicks off in Paris on July 23, we’re spotlighting researchers who’ve dedicated their life’s work to tackling the epidemic in groundbreaking ways.
Significant strides in treatment have been made since HIV/AIDS was first discovered by the medical community in the 1980s.
For over 25 years, Johnson & Johnson has been actively involved in the fight against HIV/AIDS by conducting research into treatments and prevention; forming partnerships aimed at doing things like reducing mother-to-child HIV transmission; and by helping to make lifesaving medications more accessible.
For the past 16 years, the company has also been a part of the International AIDS Society (IAS) Conference on HIV Science, where participants can share and examine the most recent HIV/AIDS research and breakthroughs with the goal of translating cutting-edge science into practice and policy.
Just ahead of this year’s conference, we caught up with some of the most brilliant minds tackling the HIV/AIDS epidemic today through groundbreaking HIV treatment and prevention work being done internally at Janssen Pharmaceuticals, part of the Johnson & Johnson family of companies, and externally through public-private partnerships.